Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and lowers the price target from $30 to $20.
U.S. stock futures were swinging on Thursday following Wednesday's mixed moves. Futures of major benchmark indices were mixed.
Biodesix shares surged over 51% in after-hours trading after major shareholder Jack W. Schuler disclosed a $1.5 million insider...
